Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus

NCT00935532 · Completed

Last updated 2026-05-28

This clinical trial compared the effects of a once-weekly injection of exenatide to a once-daily insulin injection in adults with type 2 diabetes to see how each treatment affects blood sugar levels over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 427 people

Who can join Ages 20+ · all sexes

Timeline Started 2009-07 · est. completion 2011-07

Where 22 sites · Japan

What this study is testing ClinicalTrials.gov NCT00935532 ↗

Description as written by the study sponsor.

The objectives of this clinical trial are to compare the effects of exenatide once weekly and insulin glargine on blood glucose control, body weight, lipids, safety, and tolerability.

Treatments tested

exenatide once weekly Drug

subcutaneous injection, 2.0mg, once a week;
insulin glargine also known as insulin glargine-Lantus Drug

subcutaneous injection, titrated to achieve fasting serum glucose target, once a day

Main thing measured	Change in HbA1c From Baseline to Endpoint (Week 26)
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00935532 ↗